Celestra Health Seeing Strong Customer Demand Heading into 2026
CELESTRA HEALTH SYSTEMS — AI-powered gait analysis software platform for monitoring and managing neurological diseases • celestrahealth.com
Celestra Health Systems continues to advance its goal of establishing a new gold standard in neurological clinics globally, while broadening its defensive moat through R&D investment and Intellectual Property (IP) development. The fourth quarter of 2025 marked stellar adherence rates in our clinical trials, and strong demand from pharmaceutical firms and research institutes, who have confirmed our status as a global leader in the measurement of neurological gait.
Based on our $0.5M contract with a global pharmaceutical firm, our US-based Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) clinical trial is continuing to exceed projections. Throughout the trial, we have maintained an exceptionally high adherence rate and have demonstrated the sensitivity of our platform in detecting subtle changes in disease condition.
Through our collaboration with the Technical University of Dresden (TUD), the largest MS clinic in Germany, we have completed the development of a clinically- validated suite of In-Clinic gait assessment tests, including walking, balance and jumping tests. We can now measure neurological gait, with laboratory grade accuracy, in both In-Clinic and At-Home environments.
Our 12-month Parkinson’s disease clinical trial at The Ottawa Hospital, to measure changes in patient condition in response to a novel drug therapy, is progressing well. Over the first 6 months, we have achieved a “perfect” 100% patient adherence rate.
Throughout the quarter, we continued to focus on our Research & Development activities, as we execute our strategy to become the top vendor globally for the measurement of neurological gait. We are continuing to enhance our software to objectively measure all aspects of human gait, including walking, turning, standing and stair ascending / descending. We are also developing innovative features for the measurement of spasticity and fatiguability.
Our objectives for 2026 include the continued ramp up of US and Europe market activities, as we capitalize on strong levels of interest from pharmaceutical firms and research institutes. In addition to multi-language support and the establishment of a European logistics center, we are strategically investing in cybersecurity, quality management and Software as a Medical Device (SaMD) certifications.
In partnership with Ottawa-based Carleton University’s Industrial Engineer-ing team, we are organizing User Experience (UX) focus groups with elderly populations, to optimize the usability of our platform for this key demographic.
Through participation at leading global neurology conferences, including Consortium of MS Centers (CMSC) 2026 in Charlotte (US), American Academy of Neurology (AAN) 2026 in Chicago (US) and ECTRIMS 2026 in Toronto (Canada), we will continue to raise our global profile.
We are preparing for a seed investment round in 2026, to fuel our US and European market expansion.
